Guo Tianshu, Xu Ling, Che Xiaofang, Zhang Simeng, Li Ce, Wang Jin, Gong Jing, Ma Rui, Fan Yibo, Hou Kezuo, Zhou Huiming, Hu Xuejun, Liu Yunpeng, Qu Xiujuan
Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.
Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Cell Biol Int. 2017 Jul;41(7):749-760. doi: 10.1002/cbin.10775. Epub 2017 May 5.
Lipid rafts provide a biological platform for apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). We previously reported that insulin-like growth factor 1 receptor (IGF1R) translocation into lipid rafts helped to explain TRAIL resistance. However, it was not clear whether TRAIL resistance was caused by the interaction of IGF1R with caveolin-1 (CAV1) and the non-receptor tyrosine kinase SRC in lipid rafts of gastric cancer cells. Here, we observed high IGF1R expression in TRAIL-resistant gastric cancer cells, and showed that IGF1R combined with both CAV1 and SRC in a native complex. TRAIL was shown to promote the formation of the IGF1R/CAV1/SRC tri-complex and the activation of these three molecules. Knockdown of IGF1R or CAV1 or inhibition of SRC activity reduced the formation of this tri-complex and enhanced TRAIL-induced apoptosis. Furthermore, the overexpression of microRNA-194 reversed TRAIL resistance by reducing IGF1R expression. In summary, TRAIL increased formation of the IGF1R/CAV1/SRC tri-complex and the activation of downstream survival pathways, leading to TRAIL resistance in gastric cancer cells.
脂筏为肿瘤坏死因子相关凋亡诱导配体(TRAIL)诱导的细胞凋亡提供了一个生物学平台。我们之前报道过胰岛素样生长因子1受体(IGF1R)易位至脂筏有助于解释TRAIL耐药性。然而,尚不清楚TRAIL耐药性是否是由IGF1R与胃癌细胞脂筏中的小窝蛋白-1(CAV1)和非受体酪氨酸激酶SRC相互作用所导致。在此,我们观察到TRAIL耐药的胃癌细胞中IGF1R表达较高,并表明IGF1R在一个天然复合物中与CAV1和SRC均结合。TRAIL被证明可促进IGF1R/CAV1/SRC三复合物的形成以及这三种分子的激活。敲低IGF1R或CAV1或抑制SRC活性可减少该三复合物的形成并增强TRAIL诱导的细胞凋亡。此外,微小RNA-194的过表达通过降低IGF1R表达逆转了TRAIL耐药性。总之,TRAIL增加了IGF1R/CAV1/SRC三复合物的形成以及下游存活通路的激活,导致胃癌细胞产生TRAIL耐药性。